Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health

Biomedicine and Pharmacotherapy

Volumn 59, Issue SUPPL. 1, 2005, Pages

  Tarquini, R ^a   Mazzoccoli, G ^b   Dolenti, S ^c   Gaudiano, P ^a   Comuni, C ^a   Laffi, G ^a   Perfetto, F ^a   Otsuka, K ^d   Cornelissen G ^e   Halberg, F ^e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone turnover; Circadian; Circasemidian; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CONCENTRATION (PARAMETERS); FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ADULT; CIRCADIAN RHYTHM; DATA INTERPRETATION, STATISTICAL; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE; PERIODICITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SEX CHARACTERISTICS;

EID: 27744543426     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(05)80036-8     Document Type: Article

References (22)

1. Eastel R, Simmons PS, Colwell A, Assir AMA, Burrit MF, and Russel RGG Nyctohemeral changes in bone turnover assessed by serum gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing Clin Sci 83 1992 375 382
2. Eastel R, Calvo MS, Burrit MF, Offord KP, Russel RGG, and Riggs BL Abnormality in circadian pattern of bone resorption and renal calcium conservation in type 1 osteoporosis J Clin Endocrinol Metab 74 1992 487 494
3. Hasseger C, Risteli J, Risteli L, Jensen Sb, and Christiansen C Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women J Bone Miner Res 11 1992 1307 1311
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, and Chang MS Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
5. Teitelbaum SL Bone resorption by osteoclasts Science 289 2000 1504 1508
6. Lacey DL, Timms E, Tan HL, Kelley MJ, and Dunstan CR Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 17 1998 165 176
7. Halberg F Chronobiology Annu Rev Physiol 31 1969 675 725
8. Cornélissen G, and Halberg F Chronomedicine Armitage P Colton T Encyclopedia of biostatistics vol. 1 1998 John Wiley & Sons Ltd. Chichester, UK 642 649
9. Joseph F, Chan BY, Corlett P, Durham BH, Ahmad AM, and White HD The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion http://www.endocrine-abstracts.org/ea/0009/ea0009p66.htm
10. Fu Q, Jilka RL, Manolagas SC, and O'Brien CA Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein J Biol Chem 277 2002 48868 48875
11. Vidal NO, Brandstrom H, Jonsson KB, and Ohlsson C Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids J Endocrinol 159 1998 191 195
12. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, and Spelsberg TC Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoids-induced osteoporosis Endocrinology 140 1999 4382 4389
13. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, and Ueno Y Osteoprotegerin produced by osteoblast is an important regulator in osteoclast development and function Endocrinology 141 2000 3478 3484
14. Schoppet M, Preissner KT, and Hofbauer LC RANKL ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function Arterioscler Thromb Vasc Biol 22 2002 549 553
15. Boyle WJ, Simonet WS, and Lacey DL Osteoclast differentiation and activation Nature 423 2003 337 342
16. Chagraoui H, Tulliez M, Smayra T, Komura E, Giraudier S, and Yun T Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO Blood 101 2003 2983 2989
17. Fuleihan GEH, Klerman EB, Brown EN, Choe Y, Brown EM, and Czeisler CA The parathyroid hormone circadian rhythm is truly endogenous-a General Clinical Research Center Study J Clin Endocrinol Metab 82 1997 281 286
18. Nielsen HK, Brixen K, Kassem M, Christensen SE, and Mosekilde L Diurnal rhythm in serum osteocalcin: relation with sleep, growth hormone, and PTH (1-84) Calcif Tissue Int 49 1991 373 377
19. Fraser WD, Ahmad AM, and Vora JP The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis Curr Opin Nephrol Hypertens 13 2004 437 444
20. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, and Fujise N Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1998 1329 1337
21. Indridason OS, Franzson L, and Sigurdsson G Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover Osteoporosis Int 16 2005 417 423
22. Halberg F, Engel R, Treloar AE, and Gully RJ Endogenous eosinopenia in institutionalized patients with mental deficiency-A.M.A. Arch Neurol Psychiatr 69 1953 462 469